Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001054137 | SCV001218436 | pathogenic | Medium-chain acyl-coenzyme A dehydrogenase deficiency | 2023-11-04 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 413 of the ACADM protein (p.Arg413Cys). This variant is present in population databases (rs139686925, gnomAD 0.004%). This missense change has been observed in individual(s) with MCAD deficiency (PMID: 20036593; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 850051). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ACADM protein function with a positive predictive value of 80%. This variant disrupts the p.Arg413 amino acid residue in ACADM. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 15832312, 20036593, 24718418). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV001054137 | SCV004214913 | likely pathogenic | Medium-chain acyl-coenzyme A dehydrogenase deficiency | 2023-06-05 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001054137 | SCV002092874 | likely pathogenic | Medium-chain acyl-coenzyme A dehydrogenase deficiency | 2021-09-24 | no assertion criteria provided | clinical testing |